{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:58:21Z","timestamp":1793818701912,"version":"4.6.1"},"reference-count":181,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>SOCS are a family of negative inhibitors of the molecular cascades induced by cytokines, growth factors and hormones. At molecular level, SOCS proteins inhibit the kinase activity of specific sets of receptor-associated Janus Activated Kinases (JAKs), thereby suppressing the propagation of intracellular signals. Of the eight known members, SOCS1 and SOCS3 inhibit activity of JAKs mainly induced by cytokines and can play key roles in regulation of inflammatory and immune responses. SOCS1 and SOCS3 are the most well-characterized SOCS members in skin inflammatory diseases, where their inhibitory activity on cytokine activated JAKs and consequent anti-inflammatory action has been widely investigated in epidermal keratinocytes. Structurally, SOCS1 and SOCS3 share the presence of a N-terminal domain containing a kinase inhibitory region (KIR) motif able to act as a pseudo-substrate for JAK and to inhibit its activity. During the last decades, the design and employment of SOCS1 and SOCS3-derived peptides mimicking KIR domains in experimental models of dermatoses definitively established a strong anti-inflammatory and ameliorative impact of JAK inhibition on skin inflammatory responses. Herein, we discuss the importance of the findings collected in the past on SOCS1 and SOCS3 function in the inflammatory responses associated to skin immune-mediated diseases and malignancies, for the development of the JAK inhibitor drugs. Among them, different JAK inhibitors have been introduced in the clinical practice for treatment of atopic dermatitis and psoriasis, and others are being investigated for skin diseases like alopecia areata and vitiligo.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1393799","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T04:25:01Z","timestamp":1718943901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation"],"prefix":"10.3389","volume":"15","author":[{"given":"Martina","family":"Morelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Albanesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS proteins to control JAK-STAT signalling in disease","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.727987","article-title":"SOCS proteins in immunity, inflammatory diseases, and immune-related cancer","volume":"8","author":"Sobah","year":"2021","journal-title":"Front Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00612-5","article-title":"SOCS1 and its potential clinical role in tumor","volume":"25","author":"Ying","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2015.09.037","article-title":"SOCS3 and its role in associated diseases","volume":"76","author":"Yin","year":"2015","journal-title":"Hum Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"112262","DOI":"10.1016\/j.biopha.2021.112262","article-title":"Emerging roles of suppressor of cytokine signaling 3 in human cancers","volume":"144","author":"Dai","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.582102","article-title":"SOCS, intrinsic virulence factors, and treatment of COVID-19","volume":"11","author":"Johnson","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.024","article-title":"The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability","volume":"22","author":"Babon","year":"2006","journal-title":"Mol Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(98)00067-3","article-title":"SOCS: suppressors of cytokine signalling","volume":"30","author":"Starr","year":"1998","journal-title":"Int J Biochem Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(02)02085-6","article-title":"The SOCS box: a tale of destruction and degradation","volume":"27","author":"Kile","year":"2002","journal-title":"Trends Biochem Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1011","article-title":"The SOCS box-adapting proteins for ubiquitination and proteasomal degradation","volume":"64","author":"Linossi","year":"2012","journal-title":"IUBMB Life"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.03.023","article-title":"Selective targeting of SH2 domain-phosphotyrosine interactions of src family tyrosine kinases with monobodies","volume":"429","author":"K\u00fckensh\u00f6ner","year":"2017","journal-title":"J Mol Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162111","article-title":"Rapid inflammation in mice lacking both SOCS1 and SOCS3 in hematopoietic cells","volume":"11","author":"Ushiki","year":"2016","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1252404","article-title":"VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases","volume":"18","author":"Kamura","year":"2004","journal-title":"Genes Dev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.01.024","article-title":"The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression","volume":"387","author":"Babon","year":"2009","journal-title":"J Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-116079","article-title":"Identification of a nuclear localization signal in suppressor of cytokine signaling 1","volume":"22","author":"Baetz","year":"2008","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/embj.1995.14.issue-12","article-title":"A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors","volume":"14","author":"Yoshimura","year":"1995","journal-title":"EMBO J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13194","article-title":"Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy","volume":"108","author":"Chikuma","year":"2017","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.35.24497","article-title":"Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling","volume":"274","author":"Pezet","year":"1999","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.2.375","article-title":"Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction","volume":"18","author":"Nicholson","year":"1999","journal-title":"EMBO J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.015","article-title":"Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity","volume":"36","author":"Babon","year":"2012","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/43206","article-title":"A family of cytokine-inducible inhibitors of signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.7.3770","article-title":"Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction","volume":"162","author":"Losman","year":"1999","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.50.35553","article-title":"SOCS\/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms","volume":"274","author":"Ram","year":"1999","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/mend.13.11.0368","article-title":"Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins","volume":"13","author":"Hansen","year":"1999","journal-title":"Mol Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.52.35056","article-title":"The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities","volume":"273","author":"Song","year":"1998","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M000089200","article-title":"Mechanism of STAT3 activation by insulin-like growth factor I receptor","volume":"275","author":"Zong","year":"2000","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M411043200","article-title":"Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling","volume":"279","author":"Gingras","year":"2004","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M208586200","article-title":"Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1","volume":"277","author":"Eyles","year":"2002","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.24.14395","article-title":"Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1","volume":"95","author":"Starr","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00132-7","article-title":"SOCS-1\/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo","volume":"14","author":"Naka","year":"2001","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050003","article-title":"SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential","volume":"202","author":"Davey","year":"2005","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.221","article-title":"JAB\/SOCS1\/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling","volume":"97","author":"Sporri","year":"2001","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80048-3","article-title":"SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality","volume":"98","author":"Marine","year":"1999","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003456200","article-title":"CIS3\/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2","volume":"275","author":"Sasaki","year":"2000","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.21.15985","article-title":"SOCS-3 is an insulin-induced negative regulator of insulin signaling","volume":"275","author":"Emanuelli","year":"2000","journal-title":"J Biol Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.12.004","article-title":"Inhibition of IL-6 family cytokines by SOCS3","volume":"26","author":"Babon","year":"2014","journal-title":"Semin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.100135197","article-title":"Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130","volume":"97","author":"Nicholson","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24053","article-title":"SOCS, inflammation, and cancer","volume":"2","author":"Inagaki-Ohara","year":"2013","journal-title":"JAK-STAT"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ni932","article-title":"SOCS3 regulates the plasticity of gp130 signaling","volume":"4","author":"Lang","year":"2003","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M007577200","article-title":"SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985","volume":"275","author":"Bjorbak","year":"2000","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3615","article-title":"Leptin resistance of adipocytes in obesity: role of suppressors of cytokine signaling","volume":"277","author":"Wang","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.5.2071","article-title":"The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation","volume":"96","author":"Zhang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.006","article-title":"The many faces of the SOCS box","volume":"19","author":"Piessevaux","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.11.8466","article-title":"Tissue-specific induction of SOCS gene expression by PRL","volume":"142","author":"Tam","year":"2001","journal-title":"Endocrinology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102209200","article-title":"Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase","volume":"276","author":"Peraldi","year":"2001","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00874-1","article-title":"Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues","volume":"455","author":"Emilsson","year":"1999","journal-title":"FEBS Lett"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.3.1285","article-title":"Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling","volume":"273","author":"Adams","year":"1998","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0039.2005.00532.x","article-title":"SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation","volume":"67","author":"Davey","year":"2006","journal-title":"Tissue Antigens"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2309305","DOI":"10.1080\/09546634.2024.2309305","article-title":"Leptin induces altered differentiation of keratinocytes by inducing insulin resistance: implications for metabolic syndrome-induced resistance of psoriatic therapy","volume":"35","author":"Wang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.11.02","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"O\u2019Sullivan","year":"2007","journal-title":"Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1619-y","article-title":"SOCS proteins in regulation of receptor tyrosine kinase signaling","volume":"71","author":"Kazi","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.113.16.2813","article-title":"SOCS: physiological suppressors of cytokine signaling","volume":"113","author":"Krebs","year":"2000","journal-title":"J\u00a0Cell Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00028-5","article-title":"SOCS proteins, regulators of intracellular signaling","volume":"13","author":"Chen","year":"2000","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.143","article-title":"Negative regulation of cytokine signaling pathways","volume":"18","author":"Yasukawa","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.4.2260","article-title":"IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein","volume":"166","author":"O\u2019Keefe","year":"2001","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.11.5833","article-title":"IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma","volume":"164","author":"Saito","year":"2000","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001426","article-title":"The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kr\u00fcppel-like factor-4, and it is dysregulated in psoriatic keratino","volume":"185","author":"Madonna","year":"2010","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.6964","article-title":"Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter","volume":"96","author":"Auernhammer","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123133","article-title":"Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells","volume":"10","author":"Kim","year":"2015","journal-title":"PloS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-015-3860-3","article-title":"Methylation and microRNA-mediated epigenetic regulation of SOCS3","volume":"42","author":"Boosani","year":"2015","journal-title":"Mol Biol Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04660.x","article-title":"Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia","volume":"123","author":"Liu","year":"2003","journal-title":"Br J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207787","article-title":"Differential hypermethylation of SOCS genes in ovarian and breast carcinomas","volume":"23","author":"Sutherland","year":"2004","journal-title":"Oncogene"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-011-0056-2","article-title":"Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis","volume":"34","author":"Sobti","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3892\/ijo","article-title":"Methylation status of the SOCS3 gene in human Malignant melanomas","volume":"30","author":"Tokita","year":"2007","journal-title":"Int J Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bone.2012.05.013","article-title":"miR-155 modulates TNF-\u03b1-inhibited osteogenic differentiation by targeting SOCS1 expression","volume":"51","author":"Wu","year":"2012","journal-title":"Bone"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069090","article-title":"miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling","volume":"8","author":"Collins","year":"2013","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201908_18730","article-title":"MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3","volume":"23","author":"Lin","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046082","article-title":"MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1","volume":"7","author":"Yao","year":"2012","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.356","article-title":"MicroRNAs in inflammation and immune responses","volume":"26","author":"Contreras","year":"2012","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-019-0349-y","article-title":"Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury","volume":"27","author":"Lv","year":"2020","journal-title":"Cell Death Differ"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28410","article-title":"microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK\/STAT signaling pathway by targeting SOCS-1 in rats with sepsis","volume":"234","author":"Yuan","year":"2019","journal-title":"J Cell Physiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/srep00637","article-title":"Silencing of microRNA-122 enhances interferon-\u03b1 signaling in the liver through regulating SOCS3 promoter methylation","volume":"2","author":"Yoshikawa","year":"2012","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000610","article-title":"MicroRNAs: novel regulators involved in the pathogenesis of psoriasis","volume":"2","author":"Sonkoly","year":"2007","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7759","article-title":"miR\u2212203 contributes to IL\u221217\u2212induced VEGF secretion by targeting SOCS3 in keratinocytes","volume":"16","author":"Xu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.988962","article-title":"Circulating microRNA203 and its target genes\u2019 role in psoriasis pathogenesis","volume":"9","author":"Mostafa","year":"2022","journal-title":"Front Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.042035699","article-title":"Pim serine\/threonine kinases regulate the stability of Socs-1 protein","volume":"99","author":"Chen","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303170200","article-title":"Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation","volume":"278","author":"Haan","year":"2003","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.434","article-title":"Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1","volume":"169","author":"Federici","year":"2002","journal-title":"J Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.2.984","article-title":"IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3","volume":"179","author":"Albanesi","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343370","article-title":"Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses","volume":"43","author":"Madonna","year":"2013","journal-title":"Eur J Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i15","article-title":"SOCS3 inhibits the pathological effects of IL-22 in non-melanoma skin tumor-derived keratinocytes","volume":"8","author":"Madonna","year":"2017","journal-title":"Oncotarget"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040343","article-title":"Dysregulation of suppressor of cytokine signaling 3 in keratinocytes causes skin inflammation mediated by interleukin-20 receptor-related cytokines","volume":"7","author":"Uto-Konomi","year":"2012","journal-title":"PloS One"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-106831","article-title":"Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1\/2 activation","volume":"22","author":"Madonna","year":"2008","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.69","article-title":"Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis","volume":"3","author":"Madonna","year":"2012","journal-title":"Cell Death Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700008","article-title":"Keratinocyte apoptosis in epidermal development and disease","volume":"126","author":"Raj","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01979.x","article-title":"Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis","volume":"31","author":"Horiuchi","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122462","article-title":"TGF-\u03b2-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis","volume":"130","author":"Dees","year":"2020","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0086","article-title":"SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts","volume":"32","author":"Luckett-Chastain","year":"2012","journal-title":"J Interf Cytokine Res Off J Int Soc Interf Cytokine Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.344","article-title":"The suppressor of cytokine signaling (SOCS)-3 determines keratinocyte proliferative and migratory potential during skin repair","volume":"130","author":"Linke","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1507","article-title":"Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells","volume":"69","author":"Hong","year":"2009","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/ijms23052684","article-title":"Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets","volume":"23","author":"Fania","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nm896","article-title":"SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses","volume":"9","author":"Seki","year":"2003","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-006-0007-6","article-title":"Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia","volume":"6","author":"Kubo","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600441","article-title":"SOCS1 is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions","volume":"199","author":"Takahashi","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.6.3746","article-title":"Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads","volume":"180","author":"Tanaka","year":"2008","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxf094","article-title":"A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo","volume":"14","author":"Fujimoto","year":"2002","journal-title":"Int Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1365-2222.2009.03217.x","article-title":"Suppressor of cytokine signalling 1 (SOCS1) is a physiological regulator of the asthma response","volume":"39","author":"Lee","year":"2009","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2006-0090OC","article-title":"Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma","volume":"36","author":"Harada","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"152387","DOI":"10.1016\/j.imbio.2023.152387","article-title":"Gene variants and mRNA expression analysis of SOCS3 and its association with serum IL-4 levels in atopic diseases","volume":"228","author":"Hussain","year":"2023","journal-title":"Immunobiology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/82_2017_63","article-title":"SOCS1: regulator of T cells in autoimmunity and cancer","volume":"410","author":"Ilangumaran","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/cancers14102371","article-title":"Non-melanoma skin cancer: A genetic update and future perspectives","volume":"14","author":"Zambrano-Rom\u00e1n","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045197","article-title":"Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion","volume":"7","author":"Rossa","year":"2012","journal-title":"PloS One"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403216","article-title":"SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak\/STAT pathway","volume":"18","author":"Chim","year":"2004","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445052","article-title":"Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer","volume":"45","author":"Nardinocchi","year":"2015","journal-title":"Eur J Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203551","article-title":"Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors","volume":"19","author":"Hirano","year":"2000","journal-title":"Oncogene"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208719","article-title":"Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways","volume":"24","author":"Xu","year":"2005","journal-title":"Oncogene"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23408.x","article-title":"Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma","volume":"123","author":"Li","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.10250","article-title":"Role of SOCS-1 gene on melanoma cell growth and tumor development","volume":"4","author":"Scutti","year":"2011","journal-title":"Transl Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1145-8","article-title":"Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells","volume":"70","author":"Parrillas","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1429","article-title":"Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis","volume":"68","author":"Huang","year":"2008","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.2741\/S372","article-title":"Suppressors of cytokine signalling-3 and -1 in human carcinogenesis","volume":"5","author":"Culig","year":"2013","journal-title":"Front Biosci (Schol Ed)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0274","article-title":"Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line","volume":"5","author":"Komyod","year":"2007","journal-title":"Mol Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-10-142","article-title":"Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells","volume":"10","author":"Lesinski","year":"2010","journal-title":"BMC Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.04.024","article-title":"Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2\/CCL8 induction","volume":"308","author":"Hiwatashi","year":"2011","journal-title":"Cancer Lett"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0186-1","article-title":"CCR5 blockade suppresses melanoma development through inhibition of IL-6-stat3 pathway via upregulation of SOCS3","volume":"38","author":"Tang","year":"2015","journal-title":"Inflammation"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00183","article-title":"SOCS1 mimetics and antagonists: A complementary approach to positive and negative regulation of immune function","volume":"6","author":"Ahmed","year":"2015","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.5.1309","article-title":"The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop","volume":"18","author":"Yasukawa","year":"1999","journal-title":"EMBO J"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902956","article-title":"Individual and synergistic anti-coronavirus activities of SOCS1\/3 antagonist and interferon \u03b11 peptides","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7510","article-title":"Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function","volume":"172","author":"Flowers","year":"2004","journal-title":"J Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5058","article-title":"Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist","volume":"178","author":"Waiboci","year":"2007","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900570","article-title":"HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion","volume":"183","author":"Frey","year":"2009","journal-title":"J Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01138-08","article-title":"SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system","volume":"83","author":"Ahmed","year":"2009","journal-title":"J Virol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5077","article-title":"Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing\/remi","volume":"175","author":"Mujtaba","year":"2005","journal-title":"J Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.10.018","article-title":"The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis","volume":"232","author":"Jager","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2939370","DOI":"10.1155\/2016\/2939370","article-title":"SOCS1 mimetic peptide suppresses chronic intraocular inflammatory disease (Uveitis)","volume":"2016","author":"He","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B133","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/tvst.10.3.25","article-title":"Corneal application of R9-SOCS1-KIR peptide alleviates endotoxin-induced uveitis","volume":"10","author":"Ahmed","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20111647","article-title":"New mimetic peptides of the kinase-inhibitory region (KIR) of SOCS1 through focused peptide libraries","volume":"443","author":"Doti","year":"2012","journal-title":"Biochem J"},{"key":"B135","doi-asserted-by":"publisher","first-page":"113547","DOI":"10.1016\/j.ejmech.2021.113547","article-title":"Cyclic mimetics of kinase-inhibitory region of Suppressors of Cytokine Signaling 1: Progress toward novel anti-inflammatory therapeutics","volume":"221","author":"La Manna","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B136","doi-asserted-by":"publisher","first-page":"114781","DOI":"10.1016\/j.ejmech.2022.114781","article-title":"Ad-hoc modifications of cyclic mimetics of SOCS1 protein: Structural and functional insights","volume":"243","author":"La Manna","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343748","article-title":"Therapeutic hope for psoriasis offered by SOCS (suppressor of cytokine signaling) mimetic peptide","volume":"43","author":"Kubo","year":"2013","journal-title":"Eur J Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/ph15040458","article-title":"Structure-activity relationship investigations of novel constrained chimeric peptidomimetics of SOCS3 protein targeting JAK2","volume":"15","author":"La Manna","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00664","article-title":"Chimeric peptidomimetics of SOCS 3 able to interact with JAK2 as anti-inflammatory compounds","volume":"11","author":"La Manna","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31594","article-title":"Mimetics of suppressor of cytokine signaling 3: Novel potential therapeutics in triple breast cancer","volume":"143","author":"La Manna","year":"2018","journal-title":"Int J Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.2174\/138920308785915209","article-title":"Past and future perspectives of synthetic peptide libraries","volume":"9","author":"Marasco","year":"2008","journal-title":"Curr Protein Pept Sci"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/stem.458","article-title":"A small synthetic cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson\u2019s disease","volume":"28","author":"Lonardo","year":"2010","journal-title":"Stem Cells"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806607200","article-title":"Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1","volume":"283","author":"Ponticelli","year":"2008","journal-title":"J Biol Chem"},{"key":"B144","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/antiox9080754","article-title":"Antioxidant effects of PS5, a peptidomimetic of suppressor of cytokine signaling 1, in experimental atherosclerosis","volume":"9","author":"La Manna","year":"2020","journal-title":"Antioxidants (Basel Switzerland)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2519","article-title":"SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition","volume":"20","author":"Kershaw","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2010.06.004","article-title":"IL-17 and IL-22: siblings, not twins","volume":"31","author":"Eyerich","year":"2010","journal-title":"Trends Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.003","article-title":"The multitasking organ: recent insights into skin immune function","volume":"35","author":"Di Meglio","year":"2011","journal-title":"Immunity"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00041.x","article-title":"Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes","volume":"115","author":"Albanesi","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.it.2004.03.006","article-title":"Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and \u201cType 1\u201d inflammatory gene expression","volume":"25","author":"Lew","year":"2004","journal-title":"Trends Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.317","article-title":"Identification and characterization of tumor-initiating cells in human primary cutaneous squamous cell carcinoma","volume":"132","author":"Patel","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14567","article-title":"Janus kinase inhibitors for atopic dermatitis: a promising treatment modality","volume":"46","author":"Cartron","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen A","year":"2019","journal-title":"BioDrugs"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann Rheumatol Dis"},{"key":"B156","doi-asserted-by":"publisher","first-page":"7897263","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.053","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part I: clinical and pathologic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheumatol Dis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B162","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0057","article-title":"Abrocitinib for the treatment of atopic dermatitis","volume":"15","author":"L\u00e9","year":"2023","journal-title":"Immunotherapy"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3390\/healthcare9111575","article-title":"Baricitinib: the first jak inhibitor approved in europe for the treatment of moderate to severe atopic dermatitis in adult patients","volume":"9","author":"Radi","year":"2021","journal-title":"Healthc (Basel Switzerland)"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet (London England)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","volume":"35","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B169","doi-asserted-by":"publisher","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13053","article-title":"The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review","volume":"32","author":"de Oliveira","year":"2019","journal-title":"Dermatol Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.9.1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration","volume":"28","author":"Qian","year":"2022","journal-title":"J Manage Care Spec Pharm"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.adengl.2021.05.008","article-title":"Janus kinase inhibitors in dermatology: part 2: applications in psoriasis, atopic dermatitis, and other dermatoses","volume":"112","author":"Garcia-Melendo","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet (London England)"},{"key":"B178","doi-asserted-by":"publisher","first-page":"17306","DOI":"10.3390\/ijms242417306","article-title":"Vitiligo: pathogenesis and new and emerging treatments","volume":"24","author":"Perez-Bootello","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"15593258221105370","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"B181","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/medicina59040801","article-title":"Hidradenitis suppurativa and JAK inhibitors: A review of the published literature","volume":"59","author":"Martora","year":"2023","journal-title":"Medicina (Kaunas)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1393799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T04:25:05Z","timestamp":1718943905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1393799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":181,"alternative-id":["10.3389\/fimmu.2024.1393799"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1393799","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"article-number":"1393799"}}